BLLN Key Statistics, Chart & Performance
The current stock price of BLLN is 85.94 USD. In the past month the price decreased by -17.13%.
BLLN Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| CVS | CVS HEALTH CORP | 11.72 | 101.94B | ||
| CI | THE CIGNA GROUP | 9.82 | 74.52B | ||
| BTSGU | BRIGHTSPRING HEALTH SERV - BTSG 6 3/4 02/01/27 | 124.05 | 22.82B | ||
| LH | LABCORP HOLDINGS INC | 15.92 | 20.88B | ||
| DGX | QUEST DIAGNOSTICS INC | 17.87 | 19.40B | ||
| GH | GUARDANT HEALTH INC | N/A | 14.19B | ||
| DVA | DAVITA INC | 12.07 | 7.87B | ||
| HIMS | HIMS & HERS HEALTH INC | 58.69 | 7.21B | ||
| BTSG | BRIGHTSPRING HEALTH SERVICES | 36.79 | 6.77B | ||
| CHE | CHEMED CORP | 20.2 | 6.29B | ||
| RDNT | RADNET INC | 205.79 | 6.03B | ||
| OPCH | OPTION CARE HEALTH INC | 21.34 | 5.05B |
Related stock screener links
About BLLN
Company Profile
BillionToOne Inc is a US-based company operating in Health Care Providers & Services industry. The company is headquartered in Menlo Park, California. The company went IPO on 2025-11-06. BillionToOne Inc is a United States-based precision diagnostics company. The firm provides Quantitative Counting Template (QCT) molecular counter platform, is the only technology platform that can count deoxyribonucleic acid (DNA) molecules to the single-count level and detect risk for common and severe genetic diseases. The Company’s product UNITY, is a noninvasive prenatal screening that tests fetal cell-free DNA for cystic fibrosis (CF) and spinal muscular atrophy (SMA) through a single sample of the mother's blood.
Company Info
BILLIONTOONE INC CL A
1035 O'brien Drive
Menlo Park CALIFORNIA US
Employees: 0
Phone: 16504602552
BILLIONTOONE INC CL A / BLLN FAQ
What does BILLIONTOONE INC CL A do?
BillionToOne Inc is a US-based company operating in Health Care Providers & Services industry. The company is headquartered in Menlo Park, California. The company went IPO on 2025-11-06. BillionToOne Inc is a United States-based precision diagnostics company. The firm provides Quantitative Counting Template (QCT) molecular counter platform, is the only technology platform that can count deoxyribonucleic acid (DNA) molecules to the single-count level and detect risk for common and severe genetic diseases. The Company’s product UNITY, is a noninvasive prenatal screening that tests fetal cell-free DNA for cystic fibrosis (CF) and spinal muscular atrophy (SMA) through a single sample of the mother's blood.
What is the current price of BLLN stock?
The current stock price of BLLN is 85.94 USD. The price decreased by -1.88% in the last trading session.
Does BILLIONTOONE INC CL A pay dividends?
BLLN does not pay a dividend.
What is the ChartMill rating of BILLIONTOONE INC CL A stock?
BLLN has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the ownership structure of BILLIONTOONE INC CL A (BLLN)?
You can find the ownership structure of BILLIONTOONE INC CL A (BLLN) on the Ownership tab.
What is the Short Interest ratio of BILLIONTOONE INC CL A (BLLN) stock?
The outstanding short interest for BILLIONTOONE INC CL A (BLLN) is 0.78% of its float.
BLLN Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to BLLN.
BLLN Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to BLLN. While BLLN seems to be doing ok healthwise, there are quite some concerns on its profitability.
BLLN Financial Highlights
Over the last trailing twelve months BLLN reported a non-GAAP Earnings per Share(EPS) of -0.93. The EPS increased by 49.72% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -12.69% | ||
| ROE | -23.11% | ||
| Debt/Equity | 0.31 |
BLLN Forecast & Estimates
13 analysts have analysed BLLN and the average price target is 140.59 USD. This implies a price increase of 63.59% is expected in the next year compared to the current price of 85.94.
For the next year, analysts expect an EPS growth of 118.01% and a revenue growth 97.8% for BLLN